Immutep shares are trading higher after the FDA granted the company Orphan Drug Designation for for eftilagimod alfa for the treatment of Soft Tissue Sarcoma

Benzinga Newsdesk www.benzinga.com Positive 95.3%

Neg 0% Neu 0% Pos 95.3%

Comments

No comments yet. Be the first!